1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
(
- Contribution to journal › Article
- 2018
-
Mark
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project
(
- Contribution to journal › Article
- 2017
-
Mark
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone : A pooled analysis
(
- Contribution to journal › Article
- 2016
-
Mark
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010) : A phase 3b study in refractory multiple myeloma
(
- Contribution to journal › Article
- 2015
-
Mark
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
(
- Contribution to journal › Article
- 2014
-
Mark
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study
(
- Contribution to journal › Article
- 2013
-
Mark
International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma-Related Bone Disease.
(
- Contribution to journal › Article
- 2012
-
Mark
MyelomA Genetics International Consortium
(
- Contribution to journal › Scientific review
- 2010
-
Mark
Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma.
(
- Contribution to journal › Article
- 2008
-
Mark
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
(
- Contribution to journal › Article